Contact
searchSearch
HMP Global

February 2013 - FRMC

Pertussis Vaccination and Increase in Cases
02/14/2013
Tori Socha
Despite an extensive and widely available childhood vaccination program, pertussis remains a poorly controlled vaccine-preventable disease in the United States. Infants have higher rates of pertussis compared with children in other age...
Despite an extensive and widely available childhood vaccination program, pertussis remains a poorly controlled vaccine-preventable disease in the United States. Infants have higher rates of pertussis compared with children in other age...
Despite an extensive and widely...
02/14/2013
First Report Managed Care
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
02/14/2013
Kevin L. Carter
The treatment of metastatic melanoma has been greatly enhanced by pharmacologic inhibition of the mitogen-activated protein kinase (MAPK) pathway. Trametinib mediates blockade of MAPK kinase (MEK), which is downstream of BRAF in the MAPK...
The treatment of metastatic melanoma has been greatly enhanced by pharmacologic inhibition of the mitogen-activated protein kinase (MAPK) pathway. Trametinib mediates blockade of MAPK kinase (MEK), which is downstream of BRAF in the MAPK...
The treatment of metastatic...
02/14/2013
First Report Managed Care
Rasagiline and Dopamine to Treat Parkinson’s Disease
02/14/2013
Tim Casey
Berlin, Germany—After controlling for several variables, patients with Parkinson’s disease who began therapy with rasagiline had a significantly lower probability of being hospitalized, significantly fewer hospitalizations, and shorter length...
Berlin, Germany—After controlling for several variables, patients with Parkinson’s disease who began therapy with rasagiline had a significantly lower probability of being hospitalized, significantly fewer hospitalizations, and shorter length...
Berlin, Germany—After...
02/14/2013
First Report Managed Care
Comparison of Oral Contraceptive Therapies
02/14/2013
Tim Casey
Berlin, Germany—A database analysis of insured women found that those who took 84 days of levonorgestrel/ethinyl estradiol plus ethinyl estradiol 0.01 mg for 7 days were significantly less likely to become pregnant compared with those who...
Berlin, Germany—A database analysis of insured women found that those who took 84 days of levonorgestrel/ethinyl estradiol plus ethinyl estradiol 0.01 mg for 7 days were significantly less likely to become pregnant compared with those who...
Berlin, Germany—A database...
02/14/2013
First Report Managed Care
Costs and Healthcare Utilization with Myeloproliferative Neoplasms
02/14/2013
Tim Casey
Atlanta—A retrospective cohort analysis found that total healthcare costs for Medicare patients with myeloproliferative neoplasms (MPNs) were 1.5 to 3 times higher and hospitalizations were significantly higher compared with a matched control...
Atlanta—A retrospective cohort analysis found that total healthcare costs for Medicare patients with myeloproliferative neoplasms (MPNs) were 1.5 to 3 times higher and hospitalizations were significantly higher compared with a matched control...
Atlanta—A retrospective cohort...
02/14/2013
First Report Managed Care
Phase 2 Trial of Quizartinib in AML Patients
02/14/2013
Tim Casey
Atlanta—A phase 2, open-label trial found that a subset of patients with double refractory, treatment-resistant acute myeloid leukemia (AML) achieved a clinically meaningful high response rate when taking quizartinib, an oral investigational...
Atlanta—A phase 2, open-label trial found that a subset of patients with double refractory, treatment-resistant acute myeloid leukemia (AML) achieved a clinically meaningful high response rate when taking quizartinib, an oral investigational...
Atlanta—A phase 2, open-label...
02/14/2013
First Report Managed Care
Apixaban to Treat Venous Thromboembolism
02/14/2013
Tim Casey
Atlanta—Patients who took 2.5 mg or 5 mg of apixaban twice daily for 1 year had an 80% risk reduction in recurrent nonfatal or fatal venous thromboembolism (VTE) compared with those who received placebo, according to a randomized,...
Atlanta—Patients who took 2.5 mg or 5 mg of apixaban twice daily for 1 year had an 80% risk reduction in recurrent nonfatal or fatal venous thromboembolism (VTE) compared with those who received placebo, according to a randomized,...
Atlanta—Patients who took 2.5 mg...
02/14/2013
First Report Managed Care
Phase 1/2 Trial of MLN9708 for Multiple Myeloma
02/14/2013
Tim Casey
Atlanta—Patients with previously untreated multiple myeloma, who took the investigational agent MLN9708 in combination with lenalidomide and dexamethasone, responded well to the drug regimen and tolerated the treatment, according to a phase...
Atlanta—Patients with previously untreated multiple myeloma, who took the investigational agent MLN9708 in combination with lenalidomide and dexamethasone, responded well to the drug regimen and tolerated the treatment, according to a phase...
Atlanta—Patients with previously...
02/14/2013
First Report Managed Care
Ponatinib for Patients with Rare Types of Leukemia
02/14/2013
Tim Casey
Atlanta—After a median >12 months of treatment, patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who took ponatinib responded well to the drug, according to a phase 2,...
Atlanta—After a median >12 months of treatment, patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who took ponatinib responded well to the drug, according to a phase 2,...
Atlanta—After a median >12...
02/14/2013
First Report Managed Care

Department

Conference Insider
Dabigatran Etexilate for Total Hip and Knee Replacement
02/14/2013
Tim Casey
Atlanta—Patients undergoing total hip or knee replacement who took 220 mg of dabigatran etexilate daily had few major bleeding events regardless of their body mass index (BMI), renal function, or age, according to an international,...
Atlanta—Patients undergoing total hip or knee replacement who took 220 mg of dabigatran etexilate daily had few major bleeding events regardless of their body mass index (BMI), renal function, or age, according to an international,...
Atlanta—Patients undergoing...
02/14/2013
First Report Managed Care

Behind the Bill

Behind the Bill
SCOTUS Takes on the Nondelegation Doctrine: Surprising Reactions and What They Mean for Agency Power
04/02/2025
Katie Hayes, MJ
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard...
04/02/2025
First Report Managed Care
Behind the Bill
Dr Oz’s Prescription for Making Medicaid “Viable at Every Level”
03/26/2025
Katie Hayes, MJ
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the...
03/26/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question Continues: Dr Oz's Confirmation and the Future of Medicaid
03/19/2025
Katie Hayes, MJ
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880...
03/19/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question: Can Congress Cut Spending Without Touching Medicaid?
03/12/2025
Katie Hayes, MJ
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from...
03/12/2025
First Report Managed Care
Behind the Bill
RFK Jr’s Public Comment Ban: The Silent Shift in Health Care Rulemaking
03/05/2025
Katie Hayes, MJ
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative...
03/05/2025
First Report Managed Care
Behind the Bill
Prevention Over Pills? The First 2 Weeks of Health Care’s New Direction
02/26/2025
Katie Hayes, MJ
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from...
02/26/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 2)
02/19/2025
Katie Hayes, MJ
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the...
02/19/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 1)
02/12/2025
Katie Hayes, MJ
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust...
02/12/2025
First Report Managed Care
Behind the Bill
No, President Trump Did Not Actually Sign an Executive Order That Would Increase Drug Costs for Beneficiaries
02/05/2025
Katie Hayes, MJ
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President...
02/05/2025
First Report Managed Care
Behind the Bill
Robert F. Kennedy Jr’s Confirmation and the Unexpected Turn in the Drug Pricing Debate
01/29/2025
Katie Hayes, MJ
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug...
01/29/2025
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Trending Articles

News
Authors Call for Novel, Integrated Approaches in RSV Therapeutic Research
04/27/2023
Jolynn Tumolo
In addition to encouraging increased collaboration between bioinformaticians and pharmacologists, the authors recommended the use of new approaches such as nanotechnology, molecular inhibitors, and more.
In addition to encouraging increased collaboration between bioinformaticians and pharmacologists, the authors recommended the use of new approaches such as nanotechnology, molecular inhibitors, and more.
In addition to encouraging...
04/27/2023
Pharmacy Learning Network
News
Examining the Link Between Emergency Department Use and Insurance Coverage
05/26/2023
Julie Gould
“Although Medicaid expansion has provided increased health care coverage for many previously uninsured patients, prior literature suggests that health care utilization and public spending increase with government insurance coverage,” wrote...
“Although Medicaid expansion has provided increased health care coverage for many previously uninsured patients, prior literature suggests that health care utilization and public spending increase with government insurance coverage,” wrote...
“Although Medicaid expansion has...
05/26/2023
First Report Managed Care
Quiz
RSV Vaccine Eligibility
06/21/2023
What patient demographic can now receive the FDA-approved RSV vaccine Arexvy?
What patient demographic can now receive the FDA-approved RSV vaccine Arexvy?
What patient demographic can now...
06/21/2023
First Report Managed Care
News
Men and Women With MS Perceive Functional Trajectories Differently
07/19/2023
Jolynn Tumolo
“A gap in research about the trajectories of function among men and women aging with functional limitations because of MS hinders ability to plan for future needs,” said researchers. 
“A gap in research about the trajectories of function among men and women aging with functional limitations because of MS hinders ability to plan for future needs,” said researchers. 
“A gap in research about the...
07/19/2023
First Report Managed Care
News
RSV Prefusion F Vaccine Prevents RSV Illness in Older Adults
08/10/2023
Jolynn Tumolo
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings...
08/10/2023
First Report Managed Care

February 2013 Volume 10 Issue 2

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use